Enforcement Report - Week of February 1, 2023
Enforcement Report - Week of January 18, 2023
TOKYO, May 27, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression of disease and functional impairment of amyotrophic lateral sclerosis (ALS), by the Ministry of Health, Labour and Welfare (MHLW).
Drug industry has welcomed the Food Safety and Standards Authority of India (FSSAI)’s removal of ban on methylcobalamin, commonly known as vitamin B12.
Enforcement Report - Week of December 22, 2021
Enforcement Report - Week of December 08, 2021
Enforcement Report - Week of November 17, 2021
Drug makers are in a bind due to Food Safety and Standards Authority of India (FSSAI)’s dubious stand on approval of methylcobalamin, commonly known as vitamin B12.
The pharmaceutical industry has sought intervention of Union minister of health and family welfare Mansukh Mandaviya in notifying removal of ban on methylcobalamin, commonly known as vitamin B12.
The pharmaceutical industry in the country has sought the intervention of the Central government on the issue of implementation of the arbitrary pan-India ban on methylcobalamin, by the state drug controllers (SDCs), which has not been notified as yet. Industry experts have also questioned how the ban on methylcobalamin is justified when it is still awaiting notification from the Centre.